A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

Key Points Thalidomide and prednisone maintenance after transplantation improves progression-free but not overall survival.

authors

Stewart, A Keith
Trudel, Suzanne
Bahlis, Nizar J
White, Darrell
Sabry, Waleed
Belch, Andrew
Reiman, Tony
Roy, Jean
Shustik, Chaim
Kovacs, Michael J
Rubinger, Morel
Cantin, Guy
Song, Kevin
Tompkins, Kirsty A
Marcellus, Deborah
Lacy, Martha Q
Sussman, Jonathan
Reece, Donna
Brundage, Michael
Harnett, Erica L
Shepherd, Lois
Chapman, Judy-Anne W
Meyer, Ralph

status

published

publication date

February 28, 2013

has subject area

1102 Cardiorespiratory Medicine and Haematology (FoR)
1103 Clinical Sciences (FoR)
1114 Paediatrics and Reproductive Medicine (FoR)
Academies and Institutes (MeSH)
Antineoplastic Combined Chemotherapy Protocols (MeSH)
Canada (MeSH)
Female (MeSH)
Hematopoietic Stem Cell Transplantation (MeSH)
Humans (MeSH)
Immunology (Science Metrix)
Maintenance Chemotherapy (MeSH)
Male (MeSH)
Medical Oncology (MeSH)
Middle Aged (MeSH)
Multiple Myeloma (MeSH)
Prednisone (MeSH)
Quality of Life (MeSH)
Survival Analysis (MeSH)
Thalidomide (MeSH)
Transplantation, Autologous (MeSH)
Treatment Outcome (MeSH)

published in

Blood Journal